Dr. Alberto Lleó is the director of the Memory Unit of the Neurology Department at Hospital de la Santa Creu i Sant Pau.
After obtaining his Medical degree from the University of Barcelona, he completed his specialization in Neurology at Hospital de la Santa Creu i Sant Pau in 2000. Two years later, he obtained his PhD in Medicine at the University of Barcelona and continued his education with a clinical and basic research fellowship on memory and movement disorders at the Massachusetts General Hospital, Boston (2002-2004) where he combined clinical and research tasks.
In his professional career, Dr. Alberto Lleó has combined his clinical activity with translational research projects in the field of dementias with a specific focus on the molecular bases of the disease and biomarker development. Some of his main contributions are the discovery of new genetic alterations in Alzheimer’s disease, the study of the gamma-secretase complex, and the assessment of new chemical biomarkers for Alzheimer’s disease and frontotemporal dementia.
Today, Dr. Alberto Lleó runs a translational group, leads many projects funded by public and private agencies, and collaborates regularly with numerous national and international research groups. He also coordinates the Alzheimer program of CIBERNED (Center for Networked Biomedical Research in Neurodegenerative Diseases). To date, he has authored more than 20 book chapters and over 150 publications in international journals, and his contributions have been awarded by the Spanish Society of Neurology.
- Hypermutation as an Evolutionary Mechanism for Achromobacter xylosoxidans in Cystic Fibrosis Lung Infection. Veschetti, L, Sandri, A, Johansen, HK et al. Pathogens 2020PMID:31973169
- CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. Faura, J, Bustamante, A, Penalba, A et al. J. Alzheimers Dis. 2020PMID:31958084
- Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. van der Lee, SJ, Conway, OJ, Jansen, I et al. Acta Neuropathol. 2020PMID:31955222
- A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Stamate, D, Kim, M, Proitsi, P et al. Alzheimers Dement (N Y) 2019PMID:31890857
- Reply to Letter to the Editor (HEP-19-1897). Arase, Y, Kagawa, T, Tanaka, A et al. Hepatology 2019PMID:31863598
- Letter to the Editor: might denosumab fit in PBC treatment?. Lleo, A, Ma, X, Gershwin, ME et al. Hepatology 2019PMID:31863485
- Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered. Plaz Torres, MC, Aghemo, A, Lleo, A et al. Nutrients 2019PMID:31817398
- Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Rosas, I, Martínez, C, Clarimón, J et al. Neurobiol. Aging 2019PMID:31810584
- Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. Cantero, JL, Atienza, M, Lage, C et al. Cereb. Cortex 2019PMID:31799623
- APP-derived peptides reflect neurodegeneration in frontotemporal dementia. Illán-Gala, I, Pegueroles, J, Montal, V et al. Ann Clin Transl Neurol 2019PMID:31789459
- Role of liver biopsy in hepatocellular carcinoma. Di Tommaso, L, Spadaccini, M, Donadon, M et al. World J. Gastroenterol. 2019PMID:31686761
- Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?. Veerabhadrappa, B, Delaby, C, Hirtz, C et al. Crit Rev Clin Lab Sci 2019PMID:31661652
- The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alcolea, D, Clarimón, J, Carmona-Iragui, M et al. Alzheimers Dement (N Y) 2019PMID:31650016
- Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Powers, RK, Culp-Hill, R, Ludwig, MP et al. Nat Commun 2019PMID:31628327
- Author Correction: GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Rongve, A, Witoelar, A, Ruiz, A et al. Sci Rep 2019PMID:31619746